Nasdaq · Healthcare
Celularity Inc (CELU)
As-reported financials and recent SEC filings for Celularity Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$26.6M
Net income
$-91.7M
Net margin
—
Diluted EPS
$-3.59
ROE
241.0%
P/E (TTM)
—
Market cap
—
Debt / equity
-0.9×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M |
| Gross profit | $6.5M | $39.2M | $6.8M | — | — |
| Operating income | $-61.3M | $-38.4M | $-192.3M | $-25.6M | $-109.1M |
| Net income | $-91.7M | $-57.9M | $-196.3M | $14.2M | $-100.1M |
| Diluted EPS | $-3.59 | $-2.64 | $-11.02 | $0.95 | $-5.96 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-30
View on EDGAR →8-K2026-06-25
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →SCHEDULE 13D/A2026-06-23
View on EDGAR →8-K2026-06-12
View on EDGAR →8-K2026-06-03
View on EDGAR →Largest Healthcare peers
Go deeper on CELU
Search Celularity Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.